Tipifarnib
- Generic Name
- Tipifarnib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4O
- CAS Number
- 192185-72-1
- Unique Ingredient Identifier
- MAT637500A
- Background
Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
- Indication
Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
Tipifarnib in Treating Young Patients With Refractory Leukemia
- Conditions
- Leukemia
- Locations
- 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇦🇺Princess Margaret Hospital for Children, Perth, Western Australia, Australia
R115777 in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00025454
- Locations
- 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- Radiation: radiation therapyBiological: anti-thymocyte globulinProcedure: allogeneic bone marrow transplantationProcedure: double-unit umbilical cord blood transplantationProcedure: umbilical cord blood transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00025038
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-06-26
- Target Recruit Count
- 136
- Registration Number
- NCT00005859
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
- Conditions
- LymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesLeukemiaChronic Myeloproliferative Disorders
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00005967
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
- Conditions
- Bladder Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT00047216
- Locations
- 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇨🇦St. Joseph's Hospital, Hamilton, Ontario, Canada
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
- Conditions
- Stage II Pancreatic CancerAdenocarcinoma of the PancreasStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 154
- Registration Number
- NCT00026104
- Locations
- 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00050986
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- Leukemia, Myeloid, Chronic
- Interventions
- First Posted Date
- 2002-06-21
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00040105
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
- Conditions
- Neurofibromatosis Type INeurofibroma, Plexiform
- Interventions
- Other: placebo
- First Posted Date
- 2001-07-23
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00021541
- Locations
- 🇺🇸
The Children's Hospital, Dana-Farber Cancer Institute, Boston, MA (M1034), Boston, Massachusetts, United States
🇺🇸Children's Memorial Hospital, Chicago, IL (M1484), Chicago, Illinois, United States
🇺🇸Childrens Hospital of Philadelphia, PA (M1257), Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.